Document 2794
 DOCN  M94A2794
 TI    Efficacy of AM3 (glifofosfopeptical) as modulator of immunity in the
       treatment of AIDS.
 DT    9412
 AU    Ruiz Illescas R; Torrecillas L; Teran L; Centro Medico 20 de Noviembre,
       Issste: Mexico, City.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):223 (abstract no. PB0320). Unique
       Identifier : AIDSLINE ICA10/94369781
 AB    OBJECTIVE: Investigate if AM3 has a cytoprotective effect by restoring
       cytopenias induced by the use of AZT and other chemotherapy drugs, and
       if AM3 improves response to treatment in AIDS associated neoplasm by
       stimulating immune system. METHODS: 26 men with AIDS (26-40 years old,
       median 33) in three groups; G1 = 9 patients with Kaposi Sarcoma mc
       (KSmc) stage I-II; GII = 12 pts. KS stage III; GIII = 5 pts.: 3 pts. KS
       stage IV and 2 with Immunoblastic Lymphoma. Treatment: AM3 3 grs/day;
       AZT 500 mgs/day, in GII modified CHO was added and GIII had CHOP and
       local RT additionally. The study was done august 1989-june 1993. Clinic
       evaluation every 15 days; BCC;BC;LFT monthly;--lymphocytes population
       every 3 months, cultures every 3 months and related to clinical data of
       infection. Efficacy parameters: life quality, hematologic response,
       lymphocytes population, number, type and length of infection, cancer
       progression. RESULTS: G1 = KS lesions did not increase in number or
       size, T4 lymphocytes without variation while this study was conducted (p
       < 0.0312), no critical infections, no hospitalization, stage Karnofsky;
       80-100. GII: KS lesions did not increase, T4 Lymphocytes decreased 20%
       with respect baseline during chemotherapy (variance nT = 74) no critical
       infections, no hospitalization, Karnofsky: 60-80; 20% variation of BCC
       during chemotherapy with respect to baseline. GIII: KS lesions
       progressed, tumoral lymphangitis decreased; T4 lymphocytes progressively
       decreased, all patients died before one year. BCC decreases 34%.
       CONCLUSIONS: AM3 is bone marrow cytoprotective, protects against
       infections and in groups I and II lymphocytes T4 did not change (against
       expected).
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS/IMMUNOLOGY/  *THERAPY
       Adjuvants, Immunologic/PHARMACOLOGY/*THERAPEUTIC USE  Adult
       Antineoplastic Agents, Combined/ADVERSE EFFECTS/THERAPEUTIC USE
       AIDS-Related Opportunistic Infections/PREVENTION & CONTROL  Biological
       Response Modifiers/PHARMACOLOGY/*THERAPEUTIC USE  Bone Marrow
       Diseases/CHEMICALLY INDUCED/PREVENTION & CONTROL  Calcium
       Phosphates/PHARMACOLOGY/*THERAPEUTIC USE  Comparative Study
       Cyclophosphamide/ADMINISTRATION & DOSAGE  Doxorubicin/ADMINISTRATION &
       DOSAGE  Drug Evaluation  Glycopeptides/PHARMACOLOGY/*THERAPEUTIC USE
       Human  Leukocyte Count  Lymphoma, AIDS-Related/DRUG
       THERAPY/ETIOLOGY/IMMUNOLOGY  Lymphoma, Lymphoblastic/DRUG
       THERAPY/ETIOLOGY/IMMUNOLOGY  Male  Prednisone/ADMINISTRATION & DOSAGE
       Sarcoma, Kaposi's/DRUG THERAPY/ETIOLOGY/IMMUNOLOGY  Treatment Outcome
       T4 Lymphocytes  Vincristine/ADMINISTRATION & DOSAGE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).